The report "Cellular Health Testing Market by Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs), and Region - Global Forecast to 2022", The global cellular health screening market is expected to reach USD 3.42 Billion by 2022 from USD 2.12 Billion in 2017, at a CAGR of 10.0% during the forecast period.
Don’t miss out on business opportunities in Cellular Health Testing Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=227041930
“Single test panels to dominate the market in 2017”
Based on type, the global cellular health screening market is segmented into single test panels and multi-test panels. In 2017, the single test panels segment is expected to account for the largest share of the global cellular health screening market. These panels are used to get accurate information about a single biomarker and understand how it affects the health of an individual. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.
“Based on sample collection site, the at-home segment is projected to grow at the highest CAGR”
By sample collection site, the global cellular health screening market is segmented into at-home, in-office, and other sample collection sites. The at-home segment is expected to register the highest CAGR during the forecast period. The availability of diagnostic and therapeutic products that can be used by patients at home without assistance from healthcare professionals are expected to boost the demand for cellular health screening in this segment.
Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227041930
Genova Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Quest Diagnostics (U.S.), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (U.S.)
In 2016, Telomere Diagnostics accounted for the largest share of the cellular health screening market. With its large presence and expertise in telomere testing, the company has maintained its leadership position in the market. Telomere majorly focuses on developing new products that offer innovative solutions to help people test their cellular health and take preventive and therapeutic measures as required. For instance, in 2016, the company launched the TeloYears genetic test, which helps track the cellular age of an individual based on the telomere length.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=227041930